Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Inc (NYSE: TFX) is a global medical technology leader developing devices that enhance patient care across surgical, interventional, and critical care settings. This news hub provides investors and healthcare professionals with timely updates on TFX's clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative reporting on product innovations like the UroLift system, vascular access solutions, and anesthesia devices that demonstrate Teleflex's commitment to evidence-based medicine. Our curated news collection covers essential developments including quarterly earnings, FDA clearances, partnership announcements, and clinical trial outcomes.
Key updates focus on Teleflex's core therapeutic areas: minimally invasive surgical tools, critical care devices, and urology solutions. Stay informed about technologies improving procedural safety and healthcare economics through verified press releases and objective analysis.
Bookmark this page for consolidated access to Teleflex's latest progress in medical device innovation, financial performance data, and market expansion efforts. Regularly updated to serve as your primary resource for understanding TFX's role in advancing global medical standards.
Teleflex announced a quarterly cash dividend of $0.34 per share, payable on September 15, 2021, to shareholders of record by August 16, 2021. This decision reflects the company's commitment to returning value to its shareholders through consistent dividend payments. Teleflex, a global leader in medical technologies, emphasizes innovation to meet clinical needs across various healthcare sectors, ensuring improved health outcomes for patients.
Teleflex has reported strong financial results for Q2 2021, achieving revenues of $713.5 million, a 25.8% year-over-year increase. GAAP diluted EPS surged to $1.76 from $0.24 in the prior period, while adjusted diluted EPS rose 73.6% to $3.35. The company's 2021 guidance remains unchanged, with revenue growth projected between 10.50% and 11.75%. Despite a $28-$32 million revenue headwind expected from its recent respiratory divestiture, the company maintains a positive outlook for its Interventional Urology business, anticipating over 30% growth.
Teleflex (NYSE: TFX) announced a conference call scheduled for July 29, 2021, at 8:00 a.m. ET to discuss its second-quarter financial results and provide an operational update. The call will be accessible via a live audio webcast on teleflex.com. An audio replay will be available later that day, with dial-in options provided for listeners. Teleflex is a global leader in medical technologies, focusing on enhancing patient health and healthcare delivery through innovative solutions.
Teleflex has revealed that the UroLift System yields the lowest overall complication rates among BPH treatments, based on the largest U.S. healthcare claims study presented at the European Association of Urology Congress. An analysis of over 33,000 claims showed a complication rate of 16.3% for the UroLift System at 300 days post-treatment, compared to 19.7% for TURP and 21.6% for GreenLight. The research emphasizes the UroLift System's durability with a low retreatment rate of 6.8% at 1,500 days, comparable to TURP. This data sets a new standard for evaluating minimally invasive BPH procedures.
Teleflex announced presentations at the 36th European Association of Urology Congress highlighting new data on the UroLift System for treating benign prostatic hyperplasia (BPH). Scheduled from July 8-12, these presentations will showcase real-world effectiveness and durability results, emphasizing Real-World Data to complement randomized controlled trials. The UroLift is minimally invasive, preserving sexual function, and has treated over 250,000 men globally. The studies aim to improve understanding of patient outcomes and advance treatment protocols.
Teleflex (NYSE:TFX) announced the completion of the divestiture of a significant portion of its respiratory business to Medline for $286 million, reducing to $274 million due to working capital adjustments. The divested product lines, generating $139 million in 2020, are projected to contribute flat net revenue in 2021. This move is estimated to create a $28-$32 million revenue headwind and a $0.10-$0.15 EPS dilution, approximately 1% of adjusted EPS for 2021. Proceeds will be used to pay down debt, enhancing financial flexibility.
Teleflex has released a survey indicating that men with urinary symptoms due to benign prostatic hyperplasia (BPH) often engage in extreme bathroom planning, impacting their daily activities. Conducted with 1,000 U.S. men aged 45+, the study found that 45.49% avoided enjoyable events due to urinary issues. Over 70% reported diminished energy levels from nighttime awakenings. While many men (66.81%) are interested in minimally invasive procedures, nearly 25% find current BPH medications ineffective. The UroLift System offers a promising alternative for symptom relief.
Teleflex's Executive Vice President and CFO, Thomas Powell, will present at the Raymond James 2021 Human Health Innovation Conference on June 21, 2021, at 8:40 a.m. (ET). A live audio webcast and slide presentation will be available on the Teleflex website.
Teleflex offers a range of medical technologies aimed at improving health and quality of life. Their innovative solutions cover areas such as vascular access, interventional cardiology, anesthesia, and more. The company, listed on the NYSE as TFX, is dedicated to addressing unmet clinical needs.
Teleflex has announced a definitive agreement to sell a significant portion of its Respiratory business to Medline Industries for $286 million, minus $12 million in working capital. The divested product lines generated $139 million in revenue in 2020, with flat growth expected in 2021. The transaction, anticipated to close in early Q3 2021, will incur a revenue headwind of $28-32 million and dilute adjusted earnings per share by $0.10-$0.15. Teleflex plans to use the proceeds to reduce debt and focus on core market segments.
Thomas Powell, Executive Vice President and CFO of Teleflex (NYSE: TFX), will present at the UBS Global Healthcare Virtual Conference on May 25, 2021, at 3:00 p.m. (ET). The event will include a live audio webcast and a slide presentation available on the investor section of the Teleflex website. Teleflex is known for its innovative medical technologies aimed at improving health outcomes across various fields, including vascular access and emergency medicine. The company emphasizes its commitment to addressing unmet clinical needs through its diverse product portfolio.
